CBS 2019
CBSMD教育中心
中 文

急性冠脉综合征

Abstract

Recommended Article

Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicentre FITT-STEMI trial Trends and Impact of Door-to-Balloon Time on Clinical Outcomes in Patients Aged <75, 75 to 84, and ≥85 Years With ST-Elevation Myocardial Infarction Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study New technologies for intensive prevention programs after myocardial infarction: rationale and design of the NET-IPP trial Managing Multivessel Coronary Artery Disease in Patients With ST-Elevation Myocardial Infarction: A Comprehensive Review Effect of Lipoprotein (a) Levels on Long-term Cardiovascular Outcomes in Patients with Myocardial Infarction with Nonobstructive Coronary Arteries The prognostic role of mid-range ejection fraction in ST-segment elevation myocardial infarction Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes

Original Research

JOURNAL:CBS2017 Article Link

CBS Insight with Professor Yaling Han

CBS2017 Keywords: CBS Insight; Yaling Han; NeoVas; PSP

CBS Insight interviewed Prof Yaling Han at CBS2017



Biography

Prof. Yaling Han, renowned interventional cardiologist, Academician of Chinese Academy of Engineering since 2013, Director of Institute for Cardiovascular Diseases of PLA, Director of the Key Laboratory of Acute and Severe Cardiovascular Disease of PLA, Director of Cardiology Department of Shenyang Military Region, as well as the President of Chinese College of Cardiovascular Physicians (CCCP), elected Chairperson of Chinese Society of Cardiology (CSC), FACC, FESC. Editor-In-Chief of Chinese Journal of Cadiology, JACC International Advisors, Editorial board of Circulation and the Associate editor of Cardiovascular Therapeutics, Chairperson of Great Wall International Congress of Cardiology (GW-ICC) 2017, Vice Chairperson of Transcatheter Cardiovascular Therapeutics (TCT), Chairperson of Northeast Cardiovascular Forum (NCF). Prof. Han’s major academic contributions and technical expertise are interventional treatment and antithrombotic therapy of complex critical ischemic heart diseases. As principle investigator, prof. Han has led BRIGHT, TRACK-D, I-Love-It 2, CREATE, and other multi-center, large-scale clinical researches, and participated and exchanged her research outcomes at ACC, ESC, TCT, and other important international academic conferences. As first author, prof. Han has obtained 2 items of “Second Class Prize of National Scientific and Technological Progress” and 6 items of “First Class Prize of Military and Liaoning Province”. As corresponding author, Prof. Han has published more than 700 research papers, including the international journals JAMA, JACC, etc.



Reference used in this interview


A randomized trial comparing a novel sirolimus-eluting bioresorbable scaffold with everolimus-eluting metallic stents in patients with coronary artery disease



Remarks


Date of this Interview: Dec 1st, 2017

This video is intended for professional use only by physicians and is not intented for reposting or redistribution on other external channels.

Caution: This product is intended for use by or under the direction of a physician. Prior to use, reference CBS2017.

www.cbs2017.org. All rights reserved.